Fundraising FoxSpecific Diagnostics
Mountain View, US · Delaware corporation · 1 known investors
Find your way into Specific Diagnostics
Sign up to see every warm intro you have to Specific Diagnostics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Specific Diagnostics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
bioMérieux develops in vitro diagnostic solutions for clinical laboratories and healthcare teams, covering areas such as antimicrobial stewardship, sepsis detection, respiratory infections, and COVID-19. It also provides diagnostics for food safety and quality and pharmaceutical quality control.
Founders & leadership
Investors · 1
How we know: Telegraph Hill Partners's portfolio page · a partner's Signal profile · funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$17.5M disclosed across 1 round · 2019
▶$17.5MraisedFeb 2020 · 3 investors · Other Health CareRule 506(b)
- Paul RhodesExecutive Officer, Director
- Ray MartinoDirector
- Paul GrossmanDirector
- Offering amount
- $17.5M
- Amount sold
- $17.5M
- Minimum investment
- $1
- First sale
- Aug 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 5 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| Department of DefenseDefense Health Program | Phase I | 2021 | $248.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $3M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $3M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $3M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2013 | $145.2K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Specific Diagnostics do?
- bioMérieux develops in vitro diagnostic solutions for clinical laboratories and healthcare teams, covering areas such as antimicrobial stewardship, sepsis detection, respiratory infections, and COVID-19. It also provides diagnostics for food safety and quality and pharmaceutical quality control.
- Who founded Specific Diagnostics?
- Specific Diagnostics was founded by Paul Rhodes.
- Who are Specific Diagnostics's investors?
- Specific Diagnostics's investors include Telegraph Hill Partners.
- How much funding has Specific Diagnostics raised?
- Specific Diagnostics has disclosed $17.5M raised across 1 round.
- Where is Specific Diagnostics headquartered?
- Specific Diagnostics is headquartered in Mountain View, US.